Novartis AG's Fiscal Year is From January To December - All Figures are in USD, Billions.
The item "Other-Cashflows-From-Investing-Activities" stands at 2.77 Billion United States Dollars for the trailing twelve months (TTM) period ending 09/30/2025.
Novartis AG's third quarter result of 0.831 Billion USD for the item "Other Cashflows From Investing Activities" represents an increase of 48.92 percent compared to it's second quarter result.
Also, Novartis AG's third quarter result of 0.831 Billion USD for the item "Other Cashflows From Investing Activities" represents an increase of 4.01 percent compared to it's third quarter result of last year.
Looking again at the trailing twelve months series (TTM), Novartis AG's third quarter result of 2.77 Billion USD for the item "Other Cashflows From Investing Activities" represents an increase of 1.17 percent compared to it's second quarter result.
Regarding the One-Year-Change of the series, the current value constitutes an decrease of -0.87 Billion United States Dollars compared to the value the year prior.
The 1 year change is -0.87 Billion United States Dollars.
The 3 year change is 1.99 Billion United States Dollars.
The 5 year change is 12.12 Billion United States Dollars.
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Eli Lilly and Company - Other Cashflows From Investing Activities | 905,699,262,464.00 |
![]() | Johnson & Johnson - Other Cashflows From Investing Activities | 486,508,953,600.00 |
![]() | AbbVie Inc - Other Cashflows From Investing Activities | 399,570,305,024.00 |
![]() | Roche Holding AG - Other Cashflows From Investing Activities | 317,433,206,677.55 |
![]() | AstraZeneca PLC - Other Cashflows From Investing Activities | 280,205,508,085.11 |